PMID- 37155121
OWN - NLM
STAT- MEDLINE
DCOM- 20230628
LR  - 20230701
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 23
IP  - 2
DP  - 2023 Jun
TI  - Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab 
      for Treatment of Psoriasis and Psoriatic Arthritis.
PG  - 155-163
LID - 10.1007/s40268-023-00422-w [doi]
AB  - BACKGROUND: Clinical trials have established the efficacy of brodalumab in 
      treatment of psoriasis and psoriatic arthritis. Real-world evidence is needed to 
      fully evaluate the drug. OBJECTIVE: Here we investigate drug survival and 
      clinical effectiveness of brodalumab in patients with psoriasis and psoriatic 
      arthritis in a real-world setting. METHODS: This was a retrospective 
      single-centre study enrolling patients receiving brodalumab for psoriasis at the 
      Department of Dermatology, Aarhus University Hospital, Denmark. The primary 
      endpoints were drug survival, reasons for discontinuation, percentage of patients 
      achieving a Psoriasis Area and Severity Index (PASI) </= 2 and clinical 
      effectiveness against psoriatic arthritis. RESULTS: Eighty-three patients were 
      included (mean age 49.2 +/- 17.4 years, 59.0% male, 9.6% bio-naive, mean baseline 
      PASI 10.9 +/- 6.9). Twenty-seven patients discontinued treatment primarily due to 
      ineffectiveness and adverse events (AEs). Kaplan-Meier-estimated 1-year drug 
      survival was 65.7%. An absolute Psoriasis Area and Severity Index (PASI) </= 2 was 
      achieved by 68.2% of patients at end of follow-up, by 70.0% at weeks 12-17 and by 
      76.2% after 40-60 weeks of treatment. Neither drug survival nor PASI </= 2 was 
      associated with baseline PASI >/= 10, body mass index >/= 30, previous treatment with 
      > 2 biologics or other IL-17 inhibitors in particular (P > 0.05). Psoriatic 
      arthritis remission or partial remission was achieved by 10 out of 18 patients 
      with psoriatic arthritis; treatment failure was reported in 5 patients. 
      CONCLUSIONS: Brodalumab was effective against psoriasis and psoriatic arthritis 
      in a real-world setting. The drug survival was lower than reported in other 
      real-world settings.
CI  - (c) 2023. The Author(s).
FAU - Elgaard, Cathrine Dawn Buttner
AU  - Elgaard CDB
AUID- ORCID: 0000-0003-1965-4242
AD  - Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 67, 8200, Aarhus N, Denmark.
AD  - Danish National Centre for Autoimmune Diseases, Aarhus University Hospital, 
      Aarhus, Denmark.
FAU - Iversen, Lars
AU  - Iversen L
AUID- ORCID: 0000-0003-1816-4508
AD  - Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 67, 8200, Aarhus N, Denmark.
AD  - Danish National Centre for Autoimmune Diseases, Aarhus University Hospital, 
      Aarhus, Denmark.
FAU - Hjuler, Kasper Fjellhaugen
AU  - Hjuler KF
AUID- ORCID: 0000-0001-6082-5096
AD  - Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 67, 8200, Aarhus N, Denmark. kasped@rm.dk.
AD  - Danish National Centre for Autoimmune Diseases, Aarhus University Hospital, 
      Aarhus, Denmark. kasped@rm.dk.
LA  - eng
PT  - Journal Article
DEP - 20230508
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 6ZA31Y954Z (brodalumab)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - Male
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Female
MH  - *Arthritis, Psoriatic/drug therapy
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - *Psoriasis/drug therapy/chemically induced
MH  - Treatment Outcome
PMC - PMC10293129
COIS- Cathrine Elgaard has received a personal scholarship from Novo Nordisk Foundation 
      outside of the submitted work. Dr Iversen is employed by MC2 Therapeutics A/S and 
      has served as a consultant and/or paid speaker for and/or participated in 
      clinical trials sponsored by AbbVie, Almirall, Amgen, Astra Zeneca, BMS, 
      Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo 
      Pharma, MSD, Novartis, Pfizer, Regranion, Samsung and Union Therapeutics UCB. Dr 
      Hjuler has served as a consultant and advisor for the following companies: 
      AbbVie, Bristol Myers Squibb (BMS), Janssen, LEO Pharma, UCB and Novartis, and 
      has received speaking fees or grants from AbbVie, Eli Lilly, LEO Pharma, Novartis 
      and Janssen.
EDAT- 2023/05/08 13:42
MHDA- 2023/06/28 06:42
PMCR- 2023/05/08
CRDT- 2023/05/08 11:22
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/06/28 06:42 [medline]
PHST- 2023/05/08 13:42 [pubmed]
PHST- 2023/05/08 11:22 [entrez]
PHST- 2023/05/08 00:00 [pmc-release]
AID - 10.1007/s40268-023-00422-w [pii]
AID - 422 [pii]
AID - 10.1007/s40268-023-00422-w [doi]
PST - ppublish
SO  - Drugs R D. 2023 Jun;23(2):155-163. doi: 10.1007/s40268-023-00422-w. Epub 2023 May 
      8.